Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma

Yung Lyou; Petros Grivas; Jonathan E. Rosenberg; Jean Hoffman-Censits; David I. Quinn; Daniel P. Petrylak; Matthew Galsky; Ulka Vaishampayan; Ugo De Giorgi; Sumati Gupta; Howard Burris; Jessica Rearden; Ai Li; Hao Wang; Maribel Reyes; Susan Moran; Siamak Daneshmand; Dean Bajorin; Sumanta K. Pal

doi:10.1016/j.eururo.2020.08.002

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma

Yung Lyou, Petros Grivas, Jonathan E. Rosenberg, Jean Hoffman-Censits, David I. Quinn, Daniel P. Petrylak, Matthew Galsky, Ulka Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard Burris, Jessica Rearden, Ai Li, Hao Wang, Maribel Reyes, Susan Moran, Siamak Daneshmand, Dean Bajorin, Sumanta K. Pal

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Targeted therapy is a new paradigm in treating bladder cancer. In a study using infigratinib, a drug that targets mutations in a gene called fibroblast growth factor receptor 3 (FGFR3), we found that elevated levels of phosphorous were associated with greater clinical benefit. In the future, these data may help inform treatment strategies.

Original language	English (US)
Pages (from-to)	916-924
Number of pages	9
Journal	European Urology
Volume	78
Issue number	6
DOIs	https://doi.org/10.1016/j.eururo.2020.08.002
State	Published - Dec 2020

Keywords

Biomarker
Fibroblast growth factor receptor
Hyperphosphatemia
Infigratinib
Pharmacodynamics
Pharmacokinetics
Response rate
Urothelial carcinoma

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2020.08.002

Fingerprint

Dive into the research topics of 'Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma'. Together they form a unique fingerprint.

Cite this

Lyou, Y., Grivas, P., Rosenberg, J. E., Hoffman-Censits, J., Quinn, D. I., P. Petrylak, D., Galsky, M., Vaishampayan, U., De Giorgi, U., Gupta, S., Burris, H., Rearden, J., Li, A., Wang, H., Reyes, M., Moran, S., Daneshmand, S., Bajorin, D., & Pal, S. K. (2020). Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma. European Urology, 78(6), 916-924. https://doi.org/10.1016/j.eururo.2020.08.002

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma. / Lyou, Yung; Grivas, Petros; Rosenberg, Jonathan E. et al.
In: European Urology, Vol. 78, No. 6, 12.2020, p. 916-924.

Research output: Contribution to journal › Article › peer-review

Lyou, Y, Grivas, P, Rosenberg, JE, Hoffman-Censits, J, Quinn, DI, P. Petrylak, D, Galsky, M, Vaishampayan, U, De Giorgi, U, Gupta, S, Burris, H, Rearden, J, Li, A, Wang, H, Reyes, M, Moran, S, Daneshmand, S, Bajorin, D & Pal, SK 2020, 'Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma', European Urology, vol. 78, no. 6, pp. 916-924. https://doi.org/10.1016/j.eururo.2020.08.002

Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, P. Petrylak D et al. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma. European Urology. 2020 Dec;78(6):916-924. doi: 10.1016/j.eururo.2020.08.002

@article{de419003b21d492084f2a45f7cd46189,

title = "Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma",

abstract = "Targeted therapy is a new paradigm in treating bladder cancer. In a study using infigratinib, a drug that targets mutations in a gene called fibroblast growth factor receptor 3 (FGFR3), we found that elevated levels of phosphorous were associated with greater clinical benefit. In the future, these data may help inform treatment strategies.",

keywords = "Biomarker, Fibroblast growth factor receptor, Hyperphosphatemia, Infigratinib, Pharmacodynamics, Pharmacokinetics, Response rate, Urothelial carcinoma",

author = "Yung Lyou and Petros Grivas and Rosenberg, {Jonathan E.} and Jean Hoffman-Censits and Quinn, {David I.} and {P. Petrylak}, Daniel and Matthew Galsky and Ulka Vaishampayan and {De Giorgi}, Ugo and Sumati Gupta and Howard Burris and Jessica Rearden and Ai Li and Hao Wang and Maribel Reyes and Susan Moran and Siamak Daneshmand and Dean Bajorin and Pal, {Sumanta K.}",

note = "Funding Information: Funding/Support and role of the sponsor: This work was supported by QED Therapeutics Inc. YL and SKP were supported in part by National Cancer Institute Cancer Support grant P30 CA033572 . JER and DB was supported in part by National Cancer Institute Cancer Center Support grant P30 CA008748 . Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = dec,

doi = "10.1016/j.eururo.2020.08.002",

language = "English (US)",

volume = "78",

pages = "916--924",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma

AU - Lyou, Yung

AU - Grivas, Petros

AU - Rosenberg, Jonathan E.

AU - Hoffman-Censits, Jean

AU - Quinn, David I.

AU - P. Petrylak, Daniel

AU - Galsky, Matthew

AU - Vaishampayan, Ulka

AU - De Giorgi, Ugo

AU - Gupta, Sumati

AU - Burris, Howard

AU - Rearden, Jessica

AU - Li, Ai

AU - Wang, Hao

AU - Reyes, Maribel

AU - Moran, Susan

AU - Daneshmand, Siamak

AU - Bajorin, Dean

AU - Pal, Sumanta K.

N1 - Funding Information: Funding/Support and role of the sponsor: This work was supported by QED Therapeutics Inc. YL and SKP were supported in part by National Cancer Institute Cancer Support grant P30 CA033572 . JER and DB was supported in part by National Cancer Institute Cancer Center Support grant P30 CA008748 . Publisher Copyright: © 2020

PY - 2020/12

Y1 - 2020/12

N2 - Targeted therapy is a new paradigm in treating bladder cancer. In a study using infigratinib, a drug that targets mutations in a gene called fibroblast growth factor receptor 3 (FGFR3), we found that elevated levels of phosphorous were associated with greater clinical benefit. In the future, these data may help inform treatment strategies.

AB - Targeted therapy is a new paradigm in treating bladder cancer. In a study using infigratinib, a drug that targets mutations in a gene called fibroblast growth factor receptor 3 (FGFR3), we found that elevated levels of phosphorous were associated with greater clinical benefit. In the future, these data may help inform treatment strategies.

KW - Biomarker

KW - Fibroblast growth factor receptor

KW - Hyperphosphatemia

KW - Infigratinib

KW - Pharmacodynamics

KW - Pharmacokinetics

KW - Response rate

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85089730911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089730911&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2020.08.002

DO - 10.1016/j.eururo.2020.08.002

M3 - Article

C2 - 32847703

AN - SCOPUS:85089730911

SN - 0302-2838

VL - 78

SP - 916

EP - 924

JO - European Urology

JF - European Urology

IS - 6

ER -

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this